Contact
searchSearch
HMP Global
Login
News
Nab-Paclitaxel Plus Pembrolizumab Shows Promising Safety and Activity in Advanced Urothelial Cancer
12/20/2022
In a phase 2 trial, nab-paclitaxel plus pembrolizumab demonstrated activity and promising safety for patients with urothelial cancer who progressed on platinum-based chemotherapy or were cisplatin-ineligible.
In a phase 2 trial, nab-paclitaxel plus pembrolizumab demonstrated activity and promising safety for patients with urothelial cancer who progressed on platinum-based chemotherapy or were cisplatin-ineligible.
In a phase 2 trial,...
12/20/2022
Oncology
News
New Mental Health Diagnoses Negatively Impact Survival Outcomes for Patients with Muscle-Invasive Bladder Cancer
12/01/2022
For patients with bladder cancer, a new diagnosis of a mental health disorder was associated with worse overall and bladder-cancer specific mortality, according to a recent study.
For patients with bladder cancer, a new diagnosis of a mental health disorder was associated with worse overall and bladder-cancer specific mortality, according to a recent study.
For patients with bladder...
12/01/2022
Oncology
News
Extended Partial Cystectomy vs Radical Cystectomy for Urachal Carcinoma
11/17/2022
Study findings show that extended partial cystectomy and radical cystectomy provide similar survival outcomes among patients with urachal carcinoma.
Study findings show that extended partial cystectomy and radical cystectomy provide similar survival outcomes among patients with urachal carcinoma.
Study findings show that...
11/17/2022
Oncology
News
Cytoreductive Nephrectomy Prolongs OS in Patients With Metastatic Renal Cell Carcinoma Treated With ICIs
11/09/2022
Cytoreductive nephrectomy is associated with longer OS among patients with metastatic renal cell carcinoma who received immune checkpoint inhibitors (ICIs) vs those treated with systemic therapy alone, according to a findings from a...
Cytoreductive nephrectomy is associated with longer OS among patients with metastatic renal cell carcinoma who received immune checkpoint inhibitors (ICIs) vs those treated with systemic therapy alone, according to a findings from a...
Cytoreductive nephrectomy is...
11/09/2022
Oncology
News
Neoadjuvant IMMC Followed by Transurethral Resection of Bladder Tumor Reduced Risk of Recurrence, Progression in NMIBC
10/20/2022
In a phase 2 study, 2 doses of neoadjuvant IMMC given before transurethral resection of bladder tumors was found to be a safe and effective for reducing the risk for recurrence and progression of NMIBC.
In a phase 2 study, 2 doses of neoadjuvant IMMC given before transurethral resection of bladder tumors was found to be a safe and effective for reducing the risk for recurrence and progression of NMIBC.
In a phase 2 study, 2 doses of...
10/20/2022
Oncology
News
Benign Transurethral Resection of the Prostate and High PSA Levels May Require Further Follow-Up
10/05/2022
A recent study found that, following a benign transurethral resection of the prostate, high PSA levels were associated with higher risk of prostate cancer and prostate cancer specific-death, compared to lower PSA levels.
A recent study found that, following a benign transurethral resection of the prostate, high PSA levels were associated with higher risk of prostate cancer and prostate cancer specific-death, compared to lower PSA levels.
A recent study found that,...
10/05/2022
Oncology
News
Chronic Kidney Disease Negatively Affects Outcomes for Patients Undergoing Radical Cystectomy for Bladder Cancer
09/27/2022
For patients undergoing radical cystectomy for bladder cancer, chronic kidney disease can negatively affect post-surgery outcomes.
For patients undergoing radical cystectomy for bladder cancer, chronic kidney disease can negatively affect post-surgery outcomes.
For patients undergoing radical...
09/27/2022
Oncology
News
Risk of Venous Thromboembolism Among Patients Receiving Neoadjuvant Chemotherapy for Bladder Cancer
09/16/2022
Study findings reveal patients receiving neoadjuvant therapy and radical cystectomy for bladder cancer are at significantly increased risk for venous thromboembolism.
Study findings reveal patients receiving neoadjuvant therapy and radical cystectomy for bladder cancer are at significantly increased risk for venous thromboembolism.
Study findings reveal patients...
09/16/2022
Oncology
News
Enzalutamide Yields Significant Response in Patients With Prostate Cancer Undergoing Active Surveillance
08/10/2022
In a phase 2 trial, enzalutamide plus active surveillance showed significant treatment response and tolerance among patients with low- or intermediate-risk prostate cancer when compared to active surveillance alone.
In a phase 2 trial, enzalutamide plus active surveillance showed significant treatment response and tolerance among patients with low- or intermediate-risk prostate cancer when compared to active surveillance alone.
In a phase 2 trial, enzalutamide...
08/10/2022
Oncology
News
MRI-Guided Focused Ultrasound Focal Therapy Safe, Effective for Intermediate-Risk Prostate Cancer
07/29/2022
Findings from a phase 2b trial show MRI-guided focused ultrasound focal therapy is safe and effective for treating patients with localized grade group 2 or 3 intermediate-risk prostate cancer.
Findings from a phase 2b trial show MRI-guided focused ultrasound focal therapy is safe and effective for treating patients with localized grade group 2 or 3 intermediate-risk prostate cancer.
Findings from a phase 2b trial...
07/29/2022
Oncology
News
Olaparib Adverse Events Manageable Without Discontinuation in Metastatic Prostate Cancer
07/19/2022
The most common adverse events experienced by patients treated with olaparib for metastatic castration-resistant prostate cancer were manageable through dose modification and supportive therapies, without treatment discontinuation.
The most common adverse events experienced by patients treated with olaparib for metastatic castration-resistant prostate cancer were manageable through dose modification and supportive therapies, without treatment discontinuation.
The most common adverse events...
07/19/2022
Oncology
News
Abiraterone Acetate Plus Prednisone Associated With Higher Incidence of Type 2 Diabetes vs Enzalutamide in Patients With Prostate Cancer
07/07/2022
Abiraterone acetate plus prednisone resulted in less fatigue and better health-related quality-of-life for patients with metastatic castration-resistant prostate cancer, but increased glycated hemoglobin and incidence of diabetes when...
Abiraterone acetate plus prednisone resulted in less fatigue and better health-related quality-of-life for patients with metastatic castration-resistant prostate cancer, but increased glycated hemoglobin and incidence of diabetes when...
Abiraterone acetate plus...
07/07/2022
Oncology
News
Long-term Incidence of Hematuria Following Post-Prostatectomy Radiotherapy
05/25/2022
Hematuria is common following post-prostatectomy radiotherapy, particularly among patients with medication allergies and those on anticoagulation/antiplatelet therapy, according to a study published in the Journal of Urology.
Hematuria is common following post-prostatectomy radiotherapy, particularly among patients with medication allergies and those on anticoagulation/antiplatelet therapy, according to a study published in the Journal of Urology.
Hematuria is common following...
05/25/2022
Oncology
News
Mirabegron Reduces Urinary Frequency, Improves Overactive Bladder Symptoms After Brachytherapy for Prostate Cancer
05/23/2022
Mirabergon added to tamsulosin improves frequent urination and overactive bladder symptoms among patients with prostate cancer who received brachytherapy, according to findings from a randomized trial.
Mirabergon added to tamsulosin improves frequent urination and overactive bladder symptoms among patients with prostate cancer who received brachytherapy, according to findings from a randomized trial.
Mirabergon added to tamsulosin...
05/23/2022
Oncology
Dr
Interview
Dr Cohen Reveals CCR Score May Offer ADT-Free Therapy in Higher-Risk Prostate Cancer
02/16/2021
Todd Cohen, MD, highlights how certain patients with prostate cancer may be able to forgo receipt of combined ADT.
Todd Cohen, MD, highlights how certain patients with prostate cancer may be able to forgo receipt of combined ADT.
Todd Cohen, MD, highlights how...
02/16/2021
Oncology
Dr Chi Discusses Final Results Following the TITAN Study
Videos
Dr Chi Discusses Final Results Following the TITAN Study
02/16/2021
Kim Chi, MD, discusses final analysis results from the phase 3 TITAN trial of apalutamide vs placebo for patients with metastatic CSPC receiving ADT.
Kim Chi, MD, discusses final analysis results from the phase 3 TITAN trial of apalutamide vs placebo for patients with metastatic CSPC receiving ADT.
Kim Chi, MD, discusses final...
02/16/2021
Oncology
News
Adding ADT to Radiotherapy Improves PFS in Patients With Prostate Cancer
02/02/2021
Adding ADT to radiotherapy salvage treatment reduces clinical progression and death in patients with prostate cancer.
Adding ADT to radiotherapy salvage treatment reduces clinical progression and death in patients with prostate cancer.
Adding ADT to radiotherapy...
02/02/2021
Oncology
News
No Increase in Toxicity With Ultrahypofractionated RT for Prostate Cancer
01/29/2021
Ultrahypofractionated RT yielded no increase in toxicities versus conventionally fractionated or moderately hypofractionated RT.
Ultrahypofractionated RT yielded no increase in toxicities versus conventionally fractionated or moderately hypofractionated RT.
Ultrahypofractionated RT yielded...
01/29/2021
Oncology
News
Elevated GGT Prognosticates Shorter OS in Patients With Metastatic CRPC
01/12/2021
Findings from a retrospective study suggest elevated GGT as an adverse prognosticator in patients with metastatic CRPC receiving enzalutamide.
Findings from a retrospective study suggest elevated GGT as an adverse prognosticator in patients with metastatic CRPC receiving enzalutamide.
Findings from a retrospective...
01/12/2021
Oncology
News
Higher Dementia, Depression Risk Among Patients Given ADT for Prostate Cancer
01/01/2021
Risk for dementia and depression is higher among patients who underwent ADT for prostate cancer than in those who did not.
Risk for dementia and depression is higher among patients who underwent ADT for prostate cancer than in those who did not.
Risk for dementia and depression...
01/01/2021
Oncology
Alexandra Sokolova, MD, Talks Germline Testing for Veterans With Metastatic Prostate Cancer
Videos
Alexandra Sokolova, MD, Talks Germline Testing for Veterans With Metastatic Prostate Cancer
12/28/2020
Dr Sokolova highlights a systematic approach to germline testing in veterans with metastatic prostate cancer.
Dr Sokolova highlights a systematic approach to germline testing in veterans with metastatic prostate cancer.
Dr Sokolova highlights a...
12/28/2020
Oncology
News
Radical Cystectomy, PLND Safe After Neoadjuvant Pembrolizumab for Bladder Cancer
01/23/2020
Study findings support the safety of radical cystectomy and PLND in patients with nonmetastatic bladder cancer who received neoadjuvant pembrolizumab.
Study findings support the safety of radical cystectomy and PLND in patients with nonmetastatic bladder cancer who received neoadjuvant pembrolizumab.
Study findings support the...
01/23/2020
Oncology
News
EBRT May Be Superior to CTURBT for Non–Muscle Invasive Bladder Cancer
01/20/2020
Results from a meta-analysis suggest that EBRT is superior to CTURBT as treatment for non–muscle invasive bladder cancer.
Results from a meta-analysis suggest that EBRT is superior to CTURBT as treatment for non–muscle invasive bladder cancer.
Results from a meta-analysis...
01/20/2020
Oncology
News
Laparoscopic Radical Nephroureterectomy Shows Benefit Over Open Surgery in Bladder Cancer
01/14/2020
A retrospective analysis shows that laparoscopic nephroureterectomy can benefit patients with bladder cancer because of minimal invasiveness and comparable outcomes with open nephroureterectomy.
A retrospective analysis shows that laparoscopic nephroureterectomy can benefit patients with bladder cancer because of minimal invasiveness and comparable outcomes with open nephroureterectomy.
A retrospective analysis shows...
01/14/2020
Oncology
News
Increased OS With Neoadjuvant vs Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
01/14/2020
Patients with muscle-invasive bladder cancer who are more likely to receive neoadjuvant vs adjuvant chemo have a higher rate of OS.
Patients with muscle-invasive bladder cancer who are more likely to receive neoadjuvant vs adjuvant chemo have a higher rate of OS.
Patients with muscle-invasive...
01/14/2020
Oncology
News
Radical Cystectomy Tied to Reduced Mortality in Patients With Non–Organ-Confined Bladder Cancer
01/10/2020
When compared with trimodal therapy, radical cystectomy was tied to a significant reduction in all-cause mortality in patients with non–organ-confined bladder cancer.
When compared with trimodal therapy, radical cystectomy was tied to a significant reduction in all-cause mortality in patients with non–organ-confined bladder cancer.
When compared with trimodal...
01/10/2020
Oncology
News
Combining THOLR/TUR With Epirubicin Safe, Effective for Postsurgery Bladder Cancer Therapy
01/10/2020
Combining THOLR or TUR with intravesical epirubicin within 24 hours of surgery has been shown to be safe and effective for the treatment of patients with bladder cancer tumors.
Combining THOLR or TUR with intravesical epirubicin within 24 hours of surgery has been shown to be safe and effective for the treatment of patients with bladder cancer tumors.
Combining THOLR or TUR with...
01/10/2020
Oncology
Test Your Knowledge
Quiz: Effect of New Long Non-Coding RNA on Bladder Cancer
12/20/2019
Study findings suggest that the novel long non-coding (lnc)RNA KMU15 could _____ the proliferation and progression of bladder cancer.
Study findings suggest that the novel long non-coding (lnc)RNA KMU15 could _____ the proliferation and progression of bladder cancer.
Study findings suggest that the...
12/20/2019
Oncology
Test Your Knowledge
Quiz: Urinary Calprotectin as a Bladder Cancer Tumor Marker
12/20/2019
True or False: Urinary calprotectin cannot be used as a specific tumor marker for bladder cancer.
True or False: Urinary calprotectin cannot be used as a specific tumor marker for bladder cancer.
True or False: Urinary...
12/20/2019
Oncology
Test Your Knowledge
Quiz: Does YAP1/mTOR Interaction Inhibit Bladder Cancer Progression?
12/19/2019
True or False: The interaction between YAP1 and mTOR slows down disease progression in patients with bladder cancer.
True or False: The interaction between YAP1 and mTOR slows down disease progression in patients with bladder cancer.
True or False: The interaction...
12/19/2019
Oncology
News
New Long Non-Coding RNA Promotes Bladder Cancer Progression
12/18/2019
Study results suggest that the novel long non-coding RNA KMU15 could promote the proliferation and progression of bladder cancer.
Study results suggest that the novel long non-coding RNA KMU15 could promote the proliferation and progression of bladder cancer.
Study results suggest that the...
12/18/2019
Oncology
News
Experts Rule Out Urinary Calprotectin as Tumor Marker for Bladder Cancer
12/12/2019
According to findings from a cross-sectional study, urinary calprotectin cannot be used as a specific tumor marker for bladder cancer.
According to findings from a cross-sectional study, urinary calprotectin cannot be used as a specific tumor marker for bladder cancer.
According to findings from a...
12/12/2019
Oncology
News
Increased Use of Perioperative and Neoadjuvant Chemo in Bladder Cancer
12/10/2019
Use of perioperative and neoadjuvant chemo in patients with bladder cancer has risen in Quebec, but these rates are still lower than those reported in most developed countries.
Use of perioperative and neoadjuvant chemo in patients with bladder cancer has risen in Quebec, but these rates are still lower than those reported in most developed countries.
Use of perioperative and...
12/10/2019
Oncology
News
Experts Show That YAP1/mTOR Interaction Accelerates Bladder Cancer Progression
12/05/2019
Study results suggest that the interaction between YAP1 and mTOR hastens disease progression in patients with bladder cancer.
Study results suggest that the interaction between YAP1 and mTOR hastens disease progression in patients with bladder cancer.
Study results suggest that the...
12/05/2019
Oncology
News
Study Findings Support Surveillance Imaging Past 5 Years Postsurgery in RCC
11/18/2019
Findings from a post hoc analysis support the use of surveillance imaging beyond 5 years after surgical resection in patients with intermediate- to high-risk RCC.
Findings from a post hoc analysis support the use of surveillance imaging beyond 5 years after surgical resection in patients with intermediate- to high-risk RCC.
Findings from a post hoc...
11/18/2019
Oncology
News
Oblate-Covered Everolimus Reduces Stomatitis in Patients With Metastatic RCC
11/13/2019
Oblate-covered everolimus improved the incidence rate and reduced time to stomatitis grade ≥2 in patients with mRCC.
Oblate-covered everolimus improved the incidence rate and reduced time to stomatitis grade ≥2 in patients with mRCC.
Oblate-covered everolimus...
11/13/2019
Oncology
Education and Rehab Program Improves QoL in Patients With Muscle Invasive Bladder Cancer
11/08/2019
A patient education and rehab program relieves anxiety and depression in patients with muscle invasive bladder cancer receiving chemo.
A patient education and rehab program relieves anxiety and depression in patients with muscle invasive bladder cancer receiving chemo.
A patient education and rehab...
11/08/2019
Oncology
News
5α-Reductase Inhibitors Tied to PSA Suppression in Older Patients With Prostate Cancer
11/08/2019
Study findings suggest a need for increased awareness of PSA suppression induced by the use of 5α-reductase inhibitors in older adults with prostate cancer.
Study findings suggest a need for increased awareness of PSA suppression induced by the use of 5α-reductase inhibitors in older adults with prostate cancer.
Study findings suggest a need...
11/08/2019
Oncology
Interview
Is the HULLK Key to Controlling Prostate Cancer Growth?
10/10/2019
Daniel Gioeli, PhD, and colleagues have found a potential key to regulating the progression of prostate cancer.
Daniel Gioeli, PhD, and colleagues have found a potential key to regulating the progression of prostate cancer.
Daniel Gioeli, PhD, and...
10/10/2019
Oncology
Test Your Knowledge
Quiz: Does Nivolumab–Ipilimumab Yield Long-Term Benefit in Advanced RCC?
10/01/2019
True or False: Combining nivolumab therapy with ipilimumab has shown long-term benefit in advanced RCC.
True or False: Combining nivolumab therapy with ipilimumab has shown long-term benefit in advanced RCC.
True or False: Combining...
10/01/2019
Oncology
News
Individualized Axitinib Dosing Feasible for Metastatic RCC
09/27/2019
A phase 2 study suggests that individualized axitinib dosing is a feasible therapy option for metastatic RCC.
A phase 2 study suggests that individualized axitinib dosing is a feasible therapy option for metastatic RCC.
A phase 2 study suggests that...
09/27/2019
Oncology
Avelumab Shows Promise in MMRD Endometrial Cancer, Regardless of PD-L1 Status
09/26/2019
Investigators demonstrated the promising activity of avelumab in a study of patients with MMRD endometrial cancer.
Investigators demonstrated the promising activity of avelumab in a study of patients with MMRD endometrial cancer.
Investigators demonstrated the...
09/26/2019
Oncology
Test Your Knowledge
Quiz: Erdafitinib Encourages Objective Tumor Response in Urothelial Cancer
09/25/2019
True or False: Erdafitinib is tied to an objective response in 40% of patients with locally advanced or metastatic urothelial cancer with FGFR alterations.
True or False: Erdafitinib is tied to an objective response in 40% of patients with locally advanced or metastatic urothelial cancer with FGFR alterations.
True or False: Erdafitinib is...
09/25/2019
Oncology
News
Nivolumab–Ipilimumab Combo Shows Long-Term Benefit in Advanced RCC
09/14/2019
Study findings show the long-term benefits of combining nivolumab therapy plus ipilimumab in treatment-naïve advanced RCC.
Study findings show the long-term benefits of combining nivolumab therapy plus ipilimumab in treatment-naïve advanced RCC.
Study findings show the...
09/14/2019
Oncology
Combo Therapy Promising for Cisplatin-Ineligible Metastatic Urothelial Cancer
08/23/2019
Findings from a recent trial show gemcitabine–eribulin as favorable combo for cisplatin-ineligible patients with metastatic urothelial cancer.
Findings from a recent trial show gemcitabine–eribulin as favorable combo for cisplatin-ineligible patients with metastatic urothelial cancer.
Findings from a recent trial...
08/23/2019
Oncology
Interview
ADT Tied to Alzheimer’s Disease, Dementia in Older Patients With Prostate Cancer
08/07/2019
A study led by Ravishankar Jayadevappa, PhD, showed a link between ADT and risk for Alzheimer’s disease/dementia in patients with prostate cancer.
A study led by Ravishankar Jayadevappa, PhD, showed a link between ADT and risk for Alzheimer’s disease/dementia in patients with prostate cancer.
A study led by Ravishankar...
08/07/2019
Oncology
News
Experts Validate Classifier That Can Predict Recurrence Risk in Clear-Cell RCC
04/03/2019
Researchers have created and validated a classifier that can predict whether recurrence risk is high or low in patients with localized, clear-cell RCC.
Researchers have created and validated a classifier that can predict whether recurrence risk is high or low in patients with localized, clear-cell RCC.
Researchers have created and...
04/03/2019
Oncology
Carbon Ion Radiotherapy Lowers Risk for Later Primary Cancers in Prostate Cancer
03/26/2019
Patients with localized prostate cancer who receive carbon ion radiotherapy have a lower risk for subsequent primary cancers than recipients of photon radiotherapy.
Patients with localized prostate cancer who receive carbon ion radiotherapy have a lower risk for subsequent primary cancers than recipients of photon radiotherapy.
Patients with localized prostate...
03/26/2019
Oncology
News
M371 Test Effective Biomarker of Germ Cell Tumors in Testicular Cancer
03/26/2019
Results from a recent study demonstrate the high sensitivity and specificity of the M371 test as a novel serum biomarker of germ cell tumors in seminoma and nonseminoma.
Results from a recent study demonstrate the high sensitivity and specificity of the M371 test as a novel serum biomarker of germ cell tumors in seminoma and nonseminoma.
Results from a recent study...
03/26/2019
Oncology
News
Cabozantinib Shows Promise in Treatment of Non-Clear-Cell RCC
03/07/2019
Results from a recent study suggest that cabozantinib provides significant clinical benefit to certain patients with non-clear-cell RCC.
Results from a recent study suggest that cabozantinib provides significant clinical benefit to certain patients with non-clear-cell RCC.
Results from a recent study...
03/07/2019
Oncology
Sequencing Study IDs DNA Repair Genes Tied to Prostate Cancer Risk
03/07/2019
Results from a recent study yielded a panel of 23 genes that could potentially improve treatment pathways for patients with prostate cancer.
Results from a recent study yielded a panel of 23 genes that could potentially improve treatment pathways for patients with prostate cancer.
Results from a recent study...
03/07/2019
Oncology
Current Guidelines Unreliable for Detecting Germline Variants in Prostate Cancer
02/28/2019
Recent study results suggest that NCCN guidelines are not reliable for identifying patients with prostate cancer based on whether they have pathogenic germline variants.
Recent study results suggest that NCCN guidelines are not reliable for identifying patients with prostate cancer based on whether they have pathogenic germline variants.
Recent study results suggest...
02/28/2019
Oncology
News
Hypofractionated Radiotherapy Noninferior to Conventional Radiotherapy
02/28/2019
Hypofractionated radiotherapy is noninferior to conventional radiotherapy in men with low-risk prostate cancer, yielding no differences in QoL.
Hypofractionated radiotherapy is noninferior to conventional radiotherapy in men with low-risk prostate cancer, yielding no differences in QoL.
Hypofractionated radiotherapy is...
02/28/2019
Oncology
Biomarkers Identify and Distinguish Low VS Intermediate and High Prostate Cancer Risk
01/04/2019
Large chromosomal rearrangements yield biomarkers that can identify and distinguish individuals with low versus intermediate and high risk for prostate cancer, a recent study shows.
Large chromosomal rearrangements yield biomarkers that can identify and distinguish individuals with low versus intermediate and high risk for prostate cancer, a recent study shows.
Large chromosomal rearrangements...
01/04/2019
Oncology
Low MSH2 Expression Tied to Cisplatin Resistance in Bladder Cancer
12/21/2018
Low expression of MSH2, a component of the mismatch-repair pathway, is associated with resistance to cisplatin treatment in bladder cancer, researchers report.
Low expression of MSH2, a component of the mismatch-repair pathway, is associated with resistance to cisplatin treatment in bladder cancer, researchers report.
Low expression of MSH2, a...
12/21/2018
Oncology
Recommended Surveillance in High-Risk Bladder Cancer Unheeded
10/02/2018
Patients with high- and low-risk bladder cancer undergo surveillance at comparable rates, despite recommendations calling for twice this frequency in high-risk patients.
Patients with high- and low-risk bladder cancer undergo surveillance at comparable rates, despite recommendations calling for twice this frequency in high-risk patients.
Patients with high- and low-risk...
10/02/2018
Oncology
Marital Status Tied to Risk for Death in Bladder Cancer
09/19/2018
Unmarried patients with bladder urothelial carcinoma have a higher risk for cancer-specific mortality than those who are married, according to the results of a recent study.
Unmarried patients with bladder urothelial carcinoma have a higher risk for cancer-specific mortality than those who are married, according to the results of a recent study.
Unmarried patients with bladder...
09/19/2018
Oncology
Enzyme-Based Biomarker Promising as Diagnostic Tool for Prostate Cancer
09/12/2018
Plasma GOAT enzyme levels show promise as a potential noninvasive biomarker for the detection of significant prostate cancer in individuals at risk for the disease.
Plasma GOAT enzyme levels show promise as a potential noninvasive biomarker for the detection of significant prostate cancer in individuals at risk for the disease.
Plasma GOAT enzyme levels show...
09/12/2018
Oncology
Young Cancer Survivors at Increased Risk for Endocrine Diseases
07/12/2018
Adolescent and young adult cancer survivors have a 73% higher risk for endocrine diseases than the cancer-free population.
Adolescent and young adult cancer survivors have a 73% higher risk for endocrine diseases than the cancer-free population.
Adolescent and young adult...
07/12/2018
Oncology
Robotic Surgery Noninferior to Open Surgery in Bladder Cancer Treatment
06/22/2018
Robotic surgery and traditional open surgery are equally effective in treating bladder cancer.
Robotic surgery and traditional open surgery are equally effective in treating bladder cancer.
Robotic surgery and traditional...
06/22/2018
Oncology
News
Factors Associated With High Cumulative Burden of Morbidity Among Survivors of Testicular Cancer
04/05/2018
Survivors of testicular cancer with factors associated with a high cumulative burden of morbidity score may be in need of closer monitoring.
Survivors of testicular cancer with factors associated with a high cumulative burden of morbidity score may be in need of closer monitoring.
Survivors of testicular cancer...
04/05/2018
Oncology

Recent News

News
Nab-Paclitaxel Plus Pembrolizumab Shows Promising Safety and Activity in Advanced Urothelial Cancer
12/20/2022
In a phase 2 trial, nab-paclitaxel plus pembrolizumab demonstrated activity and promising safety for patients with urothelial cancer who progressed on platinum-based chemotherapy or were cisplatin-ineligible.
In a phase 2 trial, nab-paclitaxel plus pembrolizumab demonstrated activity and promising safety for patients with urothelial cancer who progressed on platinum-based chemotherapy or were cisplatin-ineligible.
In a phase 2 trial,...
12/20/2022
Oncology
News
New Mental Health Diagnoses Negatively Impact Survival Outcomes for Patients with Muscle-Invasive Bladder Cancer
12/01/2022
For patients with bladder cancer, a new diagnosis of a mental health disorder was associated with worse overall and bladder-cancer specific mortality, according to a recent study.
For patients with bladder cancer, a new diagnosis of a mental health disorder was associated with worse overall and bladder-cancer specific mortality, according to a recent study.
For patients with bladder...
12/01/2022
Oncology
News
Extended Partial Cystectomy vs Radical Cystectomy for Urachal Carcinoma
11/17/2022
Study findings show that extended partial cystectomy and radical cystectomy provide similar survival outcomes among patients with urachal carcinoma.
Study findings show that extended partial cystectomy and radical cystectomy provide similar survival outcomes among patients with urachal carcinoma.
Study findings show that...
11/17/2022
Oncology
News
Cytoreductive Nephrectomy Prolongs OS in Patients With Metastatic Renal Cell Carcinoma Treated With ICIs
11/09/2022
Cytoreductive nephrectomy is associated with longer OS among patients with metastatic renal cell carcinoma who received immune checkpoint inhibitors (ICIs) vs those treated with systemic therapy alone, according to a findings from a...
Cytoreductive nephrectomy is associated with longer OS among patients with metastatic renal cell carcinoma who received immune checkpoint inhibitors (ICIs) vs those treated with systemic therapy alone, according to a findings from a...
Cytoreductive nephrectomy is...
11/09/2022
Oncology
News
Neoadjuvant IMMC Followed by Transurethral Resection of Bladder Tumor Reduced Risk of Recurrence, Progression in NMIBC
10/20/2022
In a phase 2 study, 2 doses of neoadjuvant IMMC given before transurethral resection of bladder tumors was found to be a safe and effective for reducing the risk for recurrence and progression of NMIBC.
In a phase 2 study, 2 doses of neoadjuvant IMMC given before transurethral resection of bladder tumors was found to be a safe and effective for reducing the risk for recurrence and progression of NMIBC.
In a phase 2 study, 2 doses of...
10/20/2022
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use